Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

References

• ThankiKGangwalRPSangamwarATJainSOral delivery of anticancer drugs: challenges and opportunitiesJ Control Release20131701154023648832
   PubMed Web of Science ®Google Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• VineisPWildCPGlobal cancer patterns: causes and preventionLancet2014383991654955724351322
   PubMed Web of Science ®Google Scholar
• FojoTLoAWPrice, value, and the cost of cancer drugsLancet Oncol20161713526758749
   PubMed Web of Science ®Google Scholar
• CojocMPeitzschCTrautmannFPolishchukLTelegeevGDDubrovskaAEmerging targets in cancer management: role of the CXCL12/CXCR4 axisOnco Targets Ther201361347136124124379
   PubMedGoogle Scholar
• AlbainKSSwannRSRuschVWRadiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trialLancet2009374968737938619632716
   PubMed Web of Science ®Google Scholar
• LiuGFranssenEFitchMIWarnerEPatient preferences for oral versus intravenous palliative chemotherapyJ Clin Oncol19971511101158996131
   PubMed Web of Science ®Google Scholar
• Le LayKMyonEHillSComparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS systemEur J Health Econ20078214515117333088
   PubMed Web of Science ®Google Scholar
• BedellCHA changing paradigm for cancer treatment: the advent of new oral chemotherapy agentsClin J Oncol Nurs2003765914705494
   PubMedGoogle Scholar
• KatoMChibaKHisakaAThe intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotei – quantitative analysis based on information from the literatureDrug Metab Pharmacokinet200318636537215618757
   PubMedGoogle Scholar
• BudhaNFrymoyerASmelickGDrug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?Clin Pharmacol Ther201292220321322739140
   PubMed Web of Science ®Google Scholar
• ChidambaramMManavalanRKathiresanKNanotherapeutics to overcome conventional cancer chemotherapy limitationsJ Pharm Pharm Sci2011141677721501554
   PubMed Web of Science ®Google Scholar
• AisnerJOverview of the changing paradigm in cancer treatment: oral chemotherapyAm J Health Syst Pharm2007649S4S7
   PubMedGoogle Scholar
• YumSISchoenhardGTiptonAJGibsonJWMiddletonJCOral Drug Delivery SystemGoogle Patents2013
   Google Scholar
• DharmadhikariNBZalaYRSinghAOral Drug Delivery SystemGoogle Patents2013
   Google Scholar
• JeanneretLSchneiderMTroxlerSBugnonOLüthiFAdhésion thérapeutique aux traitements oncologiques oraux et prise en charge interdisciplinaire [Therapeutic adherence to oral cancer therapy and interdisciplinary management]Rev Med Suisse20117296115411581160 French21721207
   PubMedGoogle Scholar
• MasaokaYTanakaYKataokaMSakumaSYamashitaSSite of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tractEur J Pharm Sci200629324025016876987
   PubMed Web of Science ®Google Scholar
• HelanderHFFändriksLSurface area of the digestive tract–revisitedScand J Gastroenterol201449668168924694282
   PubMed Web of Science ®Google Scholar
• BannaGLCollovàEGebbiaVAnticancer oral therapy: emerging related issuesCancer Treat Rev201036859560520570443
   PubMed Web of Science ®Google Scholar
• ChaurasiyaASinghAKJainGKDual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanesJ Microencapsul201229658359522439872
   PubMed Web of Science ®Google Scholar
• JibodhRALagasJSNuijenBBeijnenJHSchellensJHTaxanes: old drugs, new oral formulationsEur J Pharmacol20137171404623660368
   PubMed Web of Science ®Google Scholar
• MoesJDevelopment and Clinical Application of Oral Dosage Forms of TaxanesAmsterdam2013
   Google Scholar
• DoDPDrug delivery systems for cancer therapeuticsUS Pharm20113691215
   Google Scholar
• WangSZhouYZhuangBStar-shaped amphiphilic block polyurethane with pentaerythritol core for a hydrophobic drug delivery carrierPolym Int2016
   Web of Science ®Google Scholar
• The Cost Of Creating A New Drug Now $5 Billion, Pushing Big Pharma To ChangeForbes2013 Accessed https://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/#417710fb13c3Accessed December 1, 2017
   Google Scholar
• HillRGDrug Discovery and Development: Technology in TransitionElsevier Health SciencesLondon, UK20123038
   Google Scholar
• MeiLZhangZZhaoLPharmaceutical nanotechnology for oral delivery of anticancer drugsAdv Drug Deliv Rev201365688089023220325
   PubMed Web of Science ®Google Scholar
• HalfdanarsonTRJatoiAOral cancer chemotherapy: the critical interplay between patient education and patient safetyCurr Oncol Rep201012424725220437116
   PubMed Web of Science ®Google Scholar
• O’neillVTwelvesCOral cancer treatment: developments in chemotherapy and beyondBr J Cancer200287993393712434279
   PubMed Web of Science ®Google Scholar
• UotoKMitsuiITerasawaHSogaTFirst synthesis and cytotoxic activity of novel docetaxel analogs modified at the C18-positionBioorg Med Chem Lett199772329912996
   Web of Science ®Google Scholar
• CortesJEPazdurRDocetaxelJ Clin Oncol19951310264326557595719
   PubMed Web of Science ®Google Scholar
• VerweijJClavelMChevalierBPaclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kindAnn Oncol1994564955057918121
   PubMed Web of Science ®Google Scholar
• LwinZLeighlNEconomic evaluation of docetaxel for breast cancerExpert Opin Pharmacother200910228329019236199
   PubMed Web of Science ®Google Scholar
• KayeSScottish Gynaecological Cancer Trials GroupThe integration of docetaxel into first-line chemotherapy for ovarian cancerInt J Gynecol Cancer200111s1313311489000
   PubMedGoogle Scholar
• BelaniCPEckardtJDevelopment of docetaxel inadvanced non-small-cell lung cancerLung Cancer200446S3S1115698529
   PubMed Web of Science ®Google Scholar
• CatimelGVerweijJMattijssenVDocetaxel (Taxotere®): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neckAnn Oncol1994565335377918125
   PubMed Web of Science ®Google Scholar
• RothAMaibachRMartinelliGDocetaxel (Taxotere®)-cisplatin (TC): an effective drug combination in gastric carcinomaAnn Oncol200011330130610811496
   PubMed Web of Science ®Google Scholar
• PicusJSchultzMDocetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary resultsPaper presented at: Seminars in Oncology1999
   Google Scholar
• EngelsFSparreboomAMathotRVerweijJPotential for improvement of docetaxel-based chemotherapy: a pharmacological reviewBr J Cancer200593217317716012521
   PubMed Web of Science ®Google Scholar
• BakerJAjaniJScottéFDocetaxel-related side effects and their managementEur J Oncol Nurs2009131495919201649
   PubMed Web of Science ®Google Scholar
• SchellensJHMalingréMMKruijtzerCMFModulation of oral bioavailability of anticancer drugs: from mouse to manEur J Pharm Sci200012210311011102737
   PubMed Web of Science ®Google Scholar
• StuurmanFENuijenBBeijnenJHSchellensJHOral anticancer drugs: mechanisms of low bioavailability and strategies for improvementClin Pharmacokinet201352639941423420518
   PubMed Web of Science ®Google Scholar
• BakerSDSparreboomAVerweijJClinical pharmacokinetics of docetaxelClin Pharmacokinet200645323525216509758
   PubMed Web of Science ®Google Scholar
• LipinskiCALead- and drug-like compounds: the rule-of-five revolutionDrug Discov Today Technol20041433734124981612
   PubMedGoogle Scholar
• FayadWRickardsonLHaglundCIdentification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic propertiesChem Biol Drug Des201178454755721726416
   PubMed Web of Science ®Google Scholar
• StangierJClinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilateClin Pharmacokinet200847528529518399711
   PubMed Web of Science ®Google Scholar
• SiepmannJSiepmannFModeling of diffusion controlled drug deliveryJ Control Release2012161235136222019555
   PubMed Web of Science ®Google Scholar
• BrouwersJBrewsterMEAugustijnsPSupersaturating drug delivery systems: The answer to solubility-limited oral bioavailability?J Pharm Sci20099882549257219373886
   PubMed Web of Science ®Google Scholar
• MoesJKoolenSHuitemaASchellensJBeijnenJNuijenBPharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001)Int J Pharm2011420224425021907780
   PubMed Web of Science ®Google Scholar
• LimSMPangZWTanHYShaikhMAdinarayanaGGargSEnhancement of docetaxel solubility using binary and ternary solid dispersion systemsDrug Dev Ind Pharm201541111847185525721984
   PubMed Web of Science ®Google Scholar
• MalingréMMBeijnenJHSchellensJHOral delivery of taxanesInvest New Drugs200119215516211392449
   PubMed Web of Science ®Google Scholar
• VeberDFJohnsonSRChengH-YSmithBRWardKWKoppleKDMolecular properties that influence the oral bioavailability of drug candidatesJ Med Chem200245122615262312036371
   PubMed Web of Science ®Google Scholar
• EngelsFKTen TijeAJBakerSDEffect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelClin Pharmacol Ther200475544845415116057
   PubMed Web of Science ®Google Scholar
• UrienSBarréJMorinCPaccalyAMontayGTillementJ-PDocetaxel serum protein binding with high affinity to alpha1-acid glycoproteinInvest New Drugs19961421471518913835
   PubMed Web of Science ®Google Scholar
• EckfordPDSharomFJABC efflux pump-based resistance to chemotherapy drugsChem Rev200910972989301119583429
   PubMed Web of Science ®Google Scholar
• VarmaMVAshokrajYDeyCSPanchagnulaRP-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancementPharmacol Res200348434735912902205
   PubMed Web of Science ®Google Scholar
• ShirakawaKTakaraKTanigawaraYInteraction of Docetaxel (“Taxotere”) with Human P-GlycoproteinJpn J Cancer Res199990121380138610665657
   PubMedGoogle Scholar
• KunjachanSRychlikBStormGKiesslingFLammersTMultidrug resistance: Physiological principles and nanomedical solutionsAdv Drug Deliv Rev201365131852186524120954
   PubMed Web of Science ®Google Scholar
• BlagosklonnyMVAnalysis of FDA approved anticancer drugs reveals the future of cancer therapyCell Cycle20043810331040
   Web of Science ®Google Scholar
• BakerSDZhaoMHePCarducciMAVerweijJSparreboomASimultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometryAnal Biochem2004324227628414690692
   PubMed Web of Science ®Google Scholar
• MazzaferroSBouchemalKPonchelGOral delivery of anticancer drugs I: general considerationsDrug Discov Today2013181253422951365
   PubMed Web of Science ®Google Scholar
• EngelsFKMathotRAVerweijJAlternative drug formulations of docetaxel: a reviewAnticancer Drugs20071829510317159596
   PubMed Web of Science ®Google Scholar
• PandayVRNHuizingMTHuininkWWTBVermorkenJBBeijnenJHHypersensitivity reactions to the taxanes paclitaxel and docetaxelClin Drug Investig1997145418427
   Web of Science ®Google Scholar
• ExtraJ-MRousseauFBrunoRClavelMLe BailNMartyMPhase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusionCancer Res1993535103710428094996
   PubMed Web of Science ®Google Scholar
• MarkMWalterRMeredithDOReinhartWHCommercial taxane formulations induce stomatocytosis and increase blood viscosityBr J Pharmacol200113461207121411704640
   PubMed Web of Science ®Google Scholar
• McEnteeMSilvermanJRassnickKEnhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and ratsVet Comp Oncol20031210511219379322
   PubMedGoogle Scholar
• MalingréMMRichelDJBeijnenJHCoadministration of cyclosporine strongly enhances the oral bioavailability of docetaxelJ Clin Oncol20011941160116611181682
   PubMed Web of Science ®Google Scholar
• PatelKChowdhuryNDoddapaneniRBoakyeCHGoduguCSinghMPiperlongumine for enhancing oral bioavailability and cytotoxicity of Docetaxel in triple-negative breast cancerJ Pharm Sci2015104124417442626372815
   PubMed Web of Science ®Google Scholar
• van WaterschootRALagasJSWagenaarEAbsence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicityCancer Res200969238996900219920203
   PubMed Web of Science ®Google Scholar
• BuXZhuTMaYShenQCo-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticlesDrug Dev Ind Pharm201541576477124669977
   PubMed Web of Science ®Google Scholar
• FarokhzadOCLangerRImpact of nanotechnology on drug deliveryACS Nano200931162019206243
   PubMed Web of Science ®Google Scholar
• KompellaUBNanotechnology and drug deliveryJ Ocul Pharmacol Ther2013292898923485089
   PubMed Web of Science ®Google Scholar
• ParkKFacing the truth about nanotechnology in drug deliveryACS Nano2013797442744724490875
   PubMed Web of Science ®Google Scholar
• SunTZhangYSPangBHyunDCYangMXiaYEngineered nanoparticles for drug delivery in cancer therapyAngew Chem Int Ed Engl20145346123201236425294565
   PubMed Web of Science ®Google Scholar
• SinhaRKimGJNieSShinDMNanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug deliveryMol Cancer Ther2006581909191716928810
   PubMed Web of Science ®Google Scholar
• JiangWKimBYRutkaJTChanWCAdvances and challenges of nanotechnology-based drug delivery systemsExpert Opin Drug Deliv20074662163317970665
   PubMed Web of Science ®Google Scholar
• ParveenSMisraRSahooSKNanoparticles: a boon to drug delivery, therapeutics, diagnostics and imagingNanomedicine20128214716621703993
   PubMed Web of Science ®Google Scholar
• WalkoCMMcLeodHLPersonalizing medicine in geriatric oncologyJ Clin Oncol201432242581258625071134
   PubMed Web of Science ®Google Scholar
• WinKYFengS-SEffects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugsBiomaterials200526152713272215585275
   PubMed Web of Science ®Google Scholar
• VolkheimerGPersorption of particles: physiology and pharmacologyAdv Pharmacol Chemother197714163187329659
   PubMedGoogle Scholar
• MeiLZhangYZhengYA novel docetaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatmentNanoscale Res Lett2009412153020652101
   PubMed Web of Science ®Google Scholar
• FengS-SMeiLAnithaPGanCWZhouWPoly (lactide)–vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of DocetaxelBiomaterials200930193297330619299012
   PubMed Web of Science ®Google Scholar
• SaremiSDinarvandRKebriaeezadehAOstadSNAtyabiFEnhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studiesBiomed Res Int20132013
   PubMed Web of Science ®Google Scholar
• HuKCaoSHuFFengJEnhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluationInt J Nanomedicine201273537354522848177
   PubMed Web of Science ®Google Scholar
• MazzaferroSBouchemalKSkanjiRGueutinCChacunHPonchelGIntestinal permeation enhancement of docetaxel encapsulated into methyl-β-cyclodextrin/poly (isobutylcyanoacrylate) nanoparticles coated with thiolated chitosanJ Control Release2012162356857422902592
   PubMed Web of Science ®Google Scholar
• MazzaferroSBouchemalKMaksimenkoASkanjiROpolonPPonchelGReduced intestinal toxicity of docetaxel loaded into mucoadhesive nanoparticles, in mouse xenograft modelJ Colloid Sci Biotechnol201212210217
   Google Scholar
• WuJBuXDouLFangLShenQCo-delivery of Docetaxel and Berbamine by Chitosan/Sulfobutylether-β-Cyclodextrin nanoparticles for enhancing bioavailability and anticancer activitiesJ Biomed Nanotechnol201511101847185726502647
   PubMed Web of Science ®Google Scholar
• AhmadNAlamMAAhmadRNaqviAAAhmadFJPreparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancerArtif Cells Nanomed Biotechnol201846243244628503995
   PubMed Web of Science ®Google Scholar
• SaremiSAtyabiFAkhlaghiSPOstadSNDinarvandRThiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluationInt J Nanomedicine2011611921289989
   PubMed Web of Science ®Google Scholar
• ChimeSAOnyishiIVLipid-based drug delivery systems (LDDS): Recent advances and applications of lipids in drug deliveryAfr J Pharm Pharmacol201374830343059
   Google Scholar
• MeyerhoffAUS Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasisClin Infect Dis1999281424810028069
   PubMed Web of Science ®Google Scholar
• PillaiGNanomedicines for cancer therapy: an update of FDA approved and those under various stages of developmentSOJ Pharm Pharm Sci20141213
   Google Scholar
• PattniBSChupinVVTorchilinVPNew developments in liposomal drug deliveryChem Rev201511519109381096626010257
   PubMed Web of Science ®Google Scholar
• GregoriadisGEngineering liposomes for drug delivery: progress and problemsTrends Biotechnol199513125275378595139
   PubMed Web of Science ®Google Scholar
• SunBLuoCLiLCore-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxelColloids Surf B Biointerfaces2016143475527011346
   PubMed Web of Science ®Google Scholar
• FangGTangBChaoYCysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic studyMol Pharm20151272384239525974386
   PubMedGoogle Scholar
• ChoH-JParkJWYoonI-SKimD-DSurface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptakeInt J Nanomedicine2014949524531717
   PubMed Web of Science ®Google Scholar
• MadniATahirNRehmanMHybrid Nano-carriers for potential drug deliveryAdvanced Technology for Delivering TherapeuticsRijeka, CroatiaInTech2017
   Google Scholar
• LiuYLiKPanJLiuBFengS-SFolic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of DocetaxelBiomaterials201031233033819783040
   PubMed Web of Science ®Google Scholar
• SohailMFJavedIHussainSZFolate grafted thiolated chitosan enveloped nanoliposomes with enhanced oral bioavailability and anticancer activity of docetaxelJ Mater Chem B201643762406248
   PubMed Web of Science ®Google Scholar
• ZhangYZhuWZhangHCarboxymethyl chitosan/phospholipid bilayer-capped mesoporous carbon nanoparticles with pH-responsive and prolonged release properties for oral delivery of the antitumor drug, DocetaxelInt J Pharm2017532138439228903067
   PubMedGoogle Scholar
• Attili-QadriSKarraNNemirovskiAOral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorptionProc Natl Acad Sci U S A201311043174981750324101508
   PubMed Web of Science ®Google Scholar
• MuthuMSKulkarniSARajuAFengS-STheranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dotsBiomaterials201233123494350122306020
   PubMed Web of Science ®Google Scholar
• ShanavasASasidharanSBahadurDSrivastavaRMagnetic core-shell hybrid nanoparticles for receptor targeted anti-cancer therapy and magnetic resonance imagingJ Colloid Interface Sci201748611212027697648
   PubMed Web of Science ®Google Scholar
• YinY-MCuiF-DMuC-FDocetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluationJ Control Release20091402869419709639
   PubMed Web of Science ®Google Scholar
• VermaPMeherJGAsthanaSPawarVKChaurasiaMChourasiaMKPerspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancerDrug Deliv201623247948824901205
   PubMed Web of Science ®Google Scholar
• PandeyGMittapellyNValicherlaGRP-gp modulatory acetyl-11-keto-β-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxelColloids Surf B Biointerfaces201715527628628437753
   PubMed Web of Science ®Google Scholar
• SeoYGKimDHRamasamyTDevelopment of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effectInt J Pharm2013452141242023707964
   PubMedGoogle Scholar
• QuanQKimD-WMarasiniNPhysicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxelJ Microencapsul201330430731423101936
   PubMed Web of Science ®Google Scholar
• ChenYChenCZhengJChenZShiQLiuHDevelopment of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailabilityBiol Pharm Bull201134227828621415541
   PubMed Web of Science ®Google Scholar
• YanY-DMarasiniNChoiYKEffect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS)Eur J Drug Metab Pharmacokinet201237321722422201019
   PubMed Web of Science ®Google Scholar
• ValicherlaGRDaveKMSyedAAFormulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activitySci Rep201662689527241877
   PubMed Web of Science ®Google Scholar
• LeeEKimHLeeI-HJonSIn vivo antitumor effects of chitosan-conjugated docetaxel after oral administrationJ Control Release20091402798519712714
   PubMed Web of Science ®Google Scholar
• KhatunZNurunnabiMReeckGRChoKJLeeY-KOral delivery of taurocholic acid linked heparin–docetaxel conjugates for cancer therapyJ Control Release20131701748223665255
   PubMed Web of Science ®Google Scholar
• LiuFFengLZhangLZhangXZhangNSynthesis, characterization and antitumor evaluation of CMCS–DTX conjugates as novel delivery platform for docetaxelInt J Pharm20134511414923608199
   PubMedGoogle Scholar
• GaucherGSatturwarPJonesM-CFurtosALerouxJ-CPolymeric micelles for oral drug deliveryEur J Pharm Biopharm201076214715820600891
   PubMed Web of Science ®Google Scholar
• JonesM-CLerouxJ-CPolymeric micelles–a new generation of colloidal drug carriersEur J Pharm Biopharm199948210111110469928
   PubMed Web of Science ®Google Scholar
• WangYChenLTanLPEG–PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapyBiomaterials201435256972698524836952
   PubMed Web of Science ®Google Scholar
• ShapiraAAssarafYGEpsteinDLivneyYDBeta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assemblyPharm Res201027102175218620703895
   PubMed Web of Science ®Google Scholar
• DouJZhangHLiuXZhangMZhaiGPreparation and evaluation in vitro and in vivo of docetaxel loaded mixed micelles for oral administrationColloids Surf B Biointerfaces2014114202724157590
   PubMed Web of Science ®Google Scholar
• GuanQSunDZhangGDocetaxel-loaded self-assembly stearic acid-modified bletilla striata polysaccharide micelles and their anticancer effect: preparation, characterization, cellular uptake and in vitro evaluationMolecules201621121641
   PubMed Web of Science ®Google Scholar
• ShenYHuMQiuLSequentially dual-targeting vector with nano-in-micro structure for improved docetaxel oral delivery in vivoNanomedicine201611233071308627728994
   PubMed Web of Science ®Google Scholar
• HekmatAAttarHSeyf KordiAAImanMJaafariMRNew oral formulation and in vitro evaluation of Docetaxel-loaded nanomicellesMolecules20162191265
   PubMed Web of Science ®Google Scholar
• SongCKYoonI-SKimD-DPoloxamer-based solid dispersions for oral delivery of docetaxel: Differential effects of F68 and P85 on oral docetaxel bioavailabilityInt J Pharm2016507110210827154250
   PubMedGoogle Scholar
• RadhaGRaniTSSarvaniBA review on proniosomal drug delivery system for targeted drug actionJ Basic Clin Pharm2013424224808669
   PubMedGoogle Scholar
• LiuHHuKFengJDevelopment and characterization of TPGS modified proniosomes of docetaxelZhongguo Zhong yao za zhi=Zhongguo zhongyao zazhi= China journal of Chinese materia medica2015401937753779 Chinese26975101
   PubMedGoogle Scholar
• LiuHTuLZhouYImproved bioavailability and antitumor effect of Docetaxel by TPGS modified proniosomes: in vitro and in vivo evaluationsSci Rep2017711128127051
   PubMed Web of Science ®Google Scholar
• De JongWHBormPJDrug delivery and nanoparticles: applications and hazardsInt J Nanomedicine20083213318686775
   PubMed Web of Science ®Google Scholar
• GrabowskiNHillaireauHVergnaudJSurface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophagesInt J Pharm20154821758325448553
   PubMedGoogle Scholar
• GarciaSCGuterresSSBubolsGBBulcaoRPCharaoMFPohlmannARPolymeric nanoparticles: toxicological evaluation, cardiotoxicity, and hepatotoxicityDuranNGuterresSSAlvesOINanotoxicology: Materials, Methodologies, and AssessmentsNew YorkSpringer Science Business Media2014299324
   Google Scholar
• GiardielloMLiptrottNJMcDonaldTOAccelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapiesNat Commun2016713184110
   Google Scholar
• JohnsonJRNingY-MFarrellAJusticeRKeeganPPazdurRAccelerated approval of oncology products: the food and drug administration experienceJ Natl Cancer Inst2011103863664421422403
   PubMedGoogle Scholar
• RehmanMMadniAWebsterTJThe era of biofunctional biomaterials in orthopedics: what does the future hold?Expert Rev Med Devices201815319320429347851
   PubMed Web of Science ®Google Scholar
• WuJShenQFangLSulfobutylether-β-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxelDrug Dev Ind Pharm20133971010101922681515
   PubMed Web of Science ®Google Scholar